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Metabolically inactive insulin analog prevents type I diabetes in
prediabetic NOD mice.
D G Karounos, … , J S Bryson, D A Cohen
J Clin Invest. 1997;100(6):1344-1348. https://doi.org/10.1172/JCI119654.
The purpose of this study was to determine the relative importance of the metabolic effects of insulin for diabetes
prevention by administering insulin or an inactive insulin analog by daily subcutaneous injections to prediabetic mice. A
recombinant monomeric human insulin analog, which does not bind to the insulin receptor as a consequence of an
alteration of a single amino acid at position 25 of the B chain, was shown to be equally effective at diabetes prevention as
was intact insulin. In contrast to native insulin, the insulin analog did not cause hypoglycemia after subcutaneous
injection. The insulin analog, however, protected young adult mice from diabetes, even when it was initiated after the
onset of extensive lymphocytic infiltration of the islets. Thus, preventative therapy by daily subcutaneous injections of
insulin does not require the hypoglycemic response, or binding to the insulin receptor to prevent the onset of type I
diabetes.
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The purpose of this study was to determine the relative im-
portance of the metabolic effects of insulin for diabetes pre-
vention by administering insulin or an inactive insulin ana-
log by daily subcutaneous injections to prediabetic mice. A
recombinant monomeric human insulin analog, which does
not bind to the insulin receptor as a consequence of an alter-
ation of a single amino acid at position 25 of the B chain,
was shown to be equally effective at diabetes prevention as
was intact insulin. In contrast to native insulin, the insulin
analog did not cause hypoglycemia after subcutaneous in-
jection. The insulin analog, however, protected young adult
mice from diabetes, even when it was initiated after the on-
set of extensive lymphocytic infiltration of the islets. Thus,
preventative therapy by daily subcutaneous injections of in-
sulin does not require the hypoglycemic response, or bind-
























Insulin-dependent (type I) diabetes mellitus is an autoimmune
disease that results from destruction of insulin-secreting pan-
creatic beta cells by both humoral and cell-mediated mecha-
nisms. The nonobese diabetic (NOD) mouse, an animal model
of spontaneous diabetes, shares many features of human type I
diabetes, including abrupt onset of overt diabetes, presence of
lymphocytic infiltration of the pancreatic islet cells before the
onset of hyperglycemia (1), presence of antiislet (2, 3) and an-
tiinsulin antibodies before the onset of clinical disease (4), and
prevention of disease by immunotherapy (1). Previous studies
in the NOD model demonstrated that insulin therapy can de-
crease the incidence of diabetes when initiated in weanling
mice before the onset of significant insulitis (5). Insulin admin-
istration by subcutaneous, intravenous, nasal, or oral adminis-
tration to very young mice has been shown to decrease the
incidence of diabetes (5–10). The incidence of diabetes, how-
ever, varied in these studies depending on the routes of admin-
istration, the use of adjuvants, and the age at therapy initia-
tion. The mechanism for diabetes prevention by insulin is





downregulation of islet beta cell antigens as a consequence of




) induction of regulatory
T cells or tolerance to insulin antigenic determinants by daily




) alteration of lymphocyte function
as a direct effect of insulin binding to insulin receptors on lym-
phocytes (13–15). The purpose of this study was to determine
the relative importance of metabolic effects versus immuno-
logical effects of insulin for diabetes prevention by administer-
ing insulin or an inactive insulin analog by daily subcutaneous
injections to prediabetic NOD mice. The insulin analog, B25
Asp, does not bind to the insulin receptor or IGF-I receptor as
a consequence of the alteration of a single amino acid (see Fig.
1 [16, 17]). Drejer et al., using competitive binding assays with
hepatoma cells and adipocytes, demonstrated that the Asp





 0.005% to the IGF-I receptor (17). We dem-
onstrate that this non-glucose-altering insulin analog was
equally effective at diabetes prevention as was native insulin.
The analog protected young adult mice from diabetes, even
when it was initiated after the onset of extensive lymphocytic
infiltration of the islets. Thus, preventative therapy by daily
subcutaneous injections of insulin does not require the hy-
poglycemic response, or binding to the insulin or IGF-I recep-






NOD/MrkTacfBR mice obtained from Taconic Farms, Inc.
(Germantown, NY) were housed under specific pathogen-free condi-
tions. Only female mice were used for these studies, having a sponta-
neous incidence of diabetes of 64% at 20 wk, and 80% at 36 wk, with






























 26). The monomeric insulin analog, B25 Asp, produced by re-
combinant DNA methods, has a single amino acid alteration at posi-
tion B25 of human insulin (Fig. 1) (16), and was kindly provided by
Jens Brange (Novo-Nordisk A/S, Bagsvaerd, Denmark). The therapy
was initiated at 12 wk of age. The animals received 0.1 ml subcutane-




g (0.125 U) human neutral protamine hage-




g (0.125 U) insulin
analog B25Asp in NPH diluent (16), or vehicle (hormone-free suspen-
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Abbreviation used in this paper:
 
 NOD, nonobese diabetic.
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sion diluent fluid: 0.16% m-cresol, 0.065% phenol, 1.6% glycerin,
0.2% sodium phosphate, and water [Novo Nordisk Pharmaceuticals,
Princeton, NJ]). All animals were evaluated for diabetes onset by
monitoring blood glucose at 2–4-wk intervals. Insulin was withheld for
2 d to avoid masking diabetes onset by insulin therapy, and blood glu-
cose was then monitored. In addition, the animals were monitored
carefully when receiving their daily injections. If polyuria or weight
loss was noted, blood glucose was evaluated. Any elevated blood glu-





 16.7 mmol/liter (300 mg/dl) considered as IDDM
onset. Diabetes-free survival was calculated using the product limit or
Kaplan-Meier method with Prism software (GraphPAD Software for
Science, San Diego, CA). Analysis of variance were performed using




Randomly selected animals from each group
were killed, and the pancreas of each was examined in a double-blind
fashion for insulitis. Histological analysis of the pancreas was per-
formed using the technique of Serreze et al. (18) with minor modifica-
tions. Pancreas tissue was fixed in formalin, stained with hematoxylin
and eosin, and sectioned at three nonoverlapping levels. Six to ten
islets per mouse were individually scored by two independent observ-
ers using a semiquantitative scale ranging from 0–4 as follows: 0, nor-
mal islet with no sign of T cell infiltration; 1, islet associated with peri-
vascular, periductal leukocytic infiltration only; 2, more extensive









 25% islet destruction; and 4, complete islet destruction (18).
An insulitis score for each mouse was obtained by dividing the total




In vitro studies demonstrate that the insulin analog, B25Asp,
binds minimally to the insulin receptor as demonstrated by ad-
ipocyte receptor–binding assays (16, 19). To confirm that this
analog was inactive in vivo, we evaluated the blood glucose re-
sponse after subcutaneous administration of either the insulin
analog or an equal dose of native human insulin in prediabetic
NOD mice. As expected, B25Asp analog did not lower blood
glucose, while the native insulin significantly reduced blood
glucose levels for up to 4 h after subcutaneous injection com-










monomeric insulin analog or human NPH insulin were evalu-




). Even though compara-
ble serum levels of insulin and the analog were observed with a










In previous studies we demonstrated that the daily subcuta-




g of human insulin to young adult NOD
mice significantly reduced the incidence of diabetes, even when
initiated after the development of extensive insulitis (10). To
test the hypothesis that insulin prevents diabetes by mecha-
nisms not requiring binding to the insulin receptor, the ability
of daily subcutaneous injections of insulin or B25Asp analog
to prevent diabetes was evaluated in young adult female NOD
mice (age 12 wk). Before initiating therapy, histological evalu-
ation of representative mice confirmed that they had extensive












 4). The onset of diabetes in the different treatment




). In mice treated with vehicle alone, diabetes onset was
noted as early as 14 wk, and mice continue to develop diabetes




). In contrast, there were fewer
mice to develop diabetes in both the insulin and analog-








, Fig. 4). None of the insulin or
Figure 1. Primary structure of insulin analog B25Asp. The mono-
meric insulin analog is identical to human insulin in both the A chain 
and B chain, except for a single amino acid substitution of an aspartic 
acid for phenylalanine at position B25.
Figure 2. Blood glucose response to insulin analog and insulin. Non-
diabetic nonobese diabetic mice were given subcutaneous injection of 
5 mg of human insulin analog in NPH diluent (closed upside down tri-
angles), intact human NPH insulin (closed circles), or hormone-free 
diluent (vehicle, open circles). (A) Blood glucose was monitored ev-
ery hour after injection (mean6SEM). *P 5 0.029 (1 h); **P 5
, 0.001 (2 h); ***P 5 0.0034 (3 h). (B) Exogenous insulin levels after 
subcutaneous administration of insulin or insulin analog analyzed us-
ing an ultrasensitive radioimmunoassay specific for human insulin 















, Fig. 4). By 52 wk, diabetes-free survival was signifi-
cantly increased in both the analog and insulin-treated mice
(57 and 61%, respectively) compared to only 14% in the vehi-


















 0.0066, hazard ratio 2.59). Moreover, the non-
glucose-altering analog was equally effective at preventing dia-










We initiated therapy in adult mice with established insuli-
tis. The insulin and analog therapy prevented diabetes, but did
not decrease the degree of insulitis. The insulitis score in mice

















1.3. There was a decrease in IL-2
receptor expression as assessed by binding of anti-CD25 anti-
body in insulin and analog-treated mice when compared with
vehicle controls, suggesting that the treatments decreased the
T cell activation.
Figure 3. Diabetes onset in vehicle, insulin, or non-glucose-altering 
insulin analog–treated mice. Female nonobese diabetic mice were 
given daily injections of 5 mg of insulin analog B25 Asp (closed upside 
down triangles), insulin (closed squares), or vehicle (hormone-free di-
luent, open circles), beginning at 12 wk. Diabetes incidence was ascer-
tained by monitoring blood glucose with onset of diabetes when 
blood glucoses exceeded 16.7 mM/liter (300 mg/dl).
Figure 4. Protection from diabetes by daily subcutaneous injection of 
non-glucose-altering insulin analog or insulin. Female nonobese dia-
betic mice were given daily injections of 5 mg of insulin analog B25 
Asp (closed upside down triangles), insulin (closed squares), or
vehicle (hormone-free diluent, open circles) beginning at 12 wk.
Diabetes-free survival was analyzed by the Kaplan-Meier method. 
Diabetes-free survival was significantly increased in both the analog 
and insulin-treated mice when compared with the vehicle control 
group.
 
Table I. Prevention of Diabetes in Adult NOD Mice
 
Diabetes-free Logrank





Insulin 60.6 3.39 0.0073
Analog 56.5 2.59 0.0066
Adult NOD mice treated with insulin or insulin-analog. Route: daily





Survival proportions were calculated by the Kaplan-Meier method.
 






Administration of insulin or an inactive insulin analog, altered
by a single amino acid at position 25 of the B chain, was shown
to prevent diabetes in young adult prediabetic mice. The bio-
logical properties of this insulin analog have been character-
ized by a series of in vitro studies by Drejer et al. and Brange
et al. (17, 19). Using hepatoma cell–binding assays and free-fat
cell bioassays, Drejer at al. demonstrate that the single amino
acid alteration of the analog decreases the relative binding af-





the IGF-I receptor (17). They also show that there was a simi-
lar decrease in tyrosine kinase activation (0.2% for the analog
vs. 100% for insulin) (17). These in vitro studies demonstrate
the importance of the B25 position of the insulin B chain for
binding to the insulin receptor. Substitutions of either Leu or
Asp at position B25 were shown to dramatically reduce bind-
ing to the insulin receptor (16). This report demonstrated that
the B25 Asp insulin analog also is inactive in vivo as shown by
a lack of a hypoglycemic response after subcutaneous adminis-
tration. This observation suggests that the hypoglycemic ef-
fects of insulin and the binding of insulin to its receptor or the
IGF-I receptor are not necessary for diabetes prevention by in-
sulin.
Previous studies in which native insulin was administered
by an oral route also demonstrated a reduced incidence of dia-
betes (8, 20). The hypoglycemic effect of insulin, however, was
presumed to be reduced due to partial degradation of insulin
in the stomach, and subsequent absorption of insulin peptides
(8). In one of these studies, the insulin-treated group contin-
ued to develop diabetes, but at a slower rate than the control
group. Unfortunately, long-term followup of these animals
was not available to ascertain if diabetes onset was only tran-
siently delayed by the oral therapy (20). The advantage of our
model is that both insulin and the analog were administered by
the subcutaneous route, thus avoiding a second experimental
variable of mucosal versus subcutaneous administration of an-
tigen. In our studies, none of the insulin or analog-treated mice
developed diabetes after 36 wk of age. We demonstrated that
the subcutaneous administration of insulin analog reduced the
incidence of diabetes as effectively as insulin without the caus-
ing of hypoglycemia. For this reason, this reagent could have
therapeutic potential in humans. Immunization of NOD mice
with metabolically inactive B chain (21) or insulin peptide
B9-23 (7) in incomplete Freund’s adjuvant also reduced the in-
cidence of diabetes (7, 21), but these adjuvants are not suitable
for use in humans. A potential advantage of the analog used in
our studies over the B chain treatments is that the analog is an
intact insulin molecule altered by only a single amino acid.
Therefore, the analog contains both the A chain and B chain
of insulin, which provides the opportunity to modulate re-
sponses to known T cell determinants on both the A chain (22,
23) and B chain (24, 25) of insulin.
It is unknown in the current clinical trials whether using
subcutaneous insulin in prediabetic children and young adults
will have any harmful effects due to repeated transient epi-
sodes of hypoglycemia. Our study with B25Asp human insulin
analog demonstrated that it is possible to avoid hypoglycemia
and still prevent diabetes in young adult prediabetic mice.
The mechanisms for diabetes prevention by insulin are cur-
rently unknown, but may include downregulation of islet beta
cell antigens as a consequence of metabolic effects of insulin
(11, 12), immune modulatory effects of insulin, induction of
regulatory T cells, or tolerance by daily exposure to antigenic
determinants of insulin, or alteration of lymphocyte function
as a direct effect of insulin binding to insulin receptors on lym-
phocytes (14, 15). Evidence in support of metabolic mecha-
nisms is provided by in vitro studies that demonstrate that islet
antigen expression is decreased by lowering glucose concentra-
tion (11, 12). Immune modulatory mechanisms, however, are
suggested by the demonstration that hyperinsulinemia reduces
the number of insulin receptors on lymphocytes (15), and that
the initiation of insulin therapy in type I diabetic patients de-
creases the number of activated T lymphocytes (14). From a
mechanistic point of view, our data indicate that insulin pre-
vents diabetes primarily by processes that are independent of
the metabolic effects of insulin, and that insulin-specific im-
mune mechanisms may be more important in insulin-induced
prevention of diabetes. Finally, it is clear from these animal
studies that inactive insulin analogs may prove invaluable
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